Literature DB >> 16250555

The pharmacologic modulation of the hypermetabolic response to burns.

Clifford T Pereira1, David N Herndon.   

Abstract

Patients with burns less than 40% TBSA do not have catabolism unless sepsis develops. Those with burns more than 40% TBSA always experience catabolism, which causes metabolic derangements that persist for at least 1 year after the injury in most body tissues. The accomplishments of the past decade have placed us in the midst of an exciting paradigm shift from what used to be a primary concern (ie, mortality) to areas that are more likely to enhance the quality of life of burn survivors. Modulating postburn hypermetabolism for the burned patient is of overwhelming importance in both the immediate care stage and the rehabilitative stage. Postburn hypermetabolism cannot be completely reversed but may be manipulated by nonpharmacologic and pharmacologic means. Early burn wound excision and complete wound closure, prevention of sepsis, the maintenance of thermal neutrality for the patient by elevation of the ambient temperature, and graded resistance exercises during convalescence are simple, highly effective primary treatment goals. Although the initial burn injury and sepsis-related complications principally determine the extent of the metabolic response in burn victims, obligatory activity, background- and procedural-related pain, and anxiety also greatly increase metabolic rates. Judicious maximal narcotic support, appropriate sedation, and supportive psychotherapy are mandatory if their effects are to be minimized. Several anabolic and anticatabolic agents are available for use during immediate care and rehabilitation. Exogenous, continuous low-dose insulin infusion, beta-blockade with propranolol, and the use of the synthetic testosterone analogue oxandrolone are the most cost-effective and least toxic therapies to date. These greatly assist therapeutic minimization of the loss of lean body mass and linear growth delay and are effective in burned patients with and without sepsis. Adverse effects, cost benefits, and the ease of administration and monitoring must be examined when considering the possibility of their use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16250555     DOI: 10.1016/j.yasu.2005.05.005

Source DB:  PubMed          Journal:  Adv Surg        ISSN: 0065-3411


  25 in total

1.  Burn mortality in patients with preexisting cardiovascular disease.

Authors:  Laquanda Knowlin; Trista Reid; Felicia Williams; Bruce Cairns; Anthony Charles
Journal:  Burns       Date:  2017-02-08       Impact factor: 2.744

2.  Short-term metformin and exercise training effects on strength, aerobic capacity, glycemic control, and mitochondrial function in children with burn injury.

Authors:  Eric Rivas; David N Herndon; Craig Porter; Walter Meyer; Oscar E Suman
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-11-14       Impact factor: 4.310

Review 3.  Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.

Authors:  Eduardo I Gus; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Burns       Date:  2019-12-15       Impact factor: 2.744

4.  β-Adrenergic blockade does not impair the skin blood flow sensitivity to local heating in burned and nonburned skin under neutral and hot environments in children.

Authors:  Eric Rivas; Serina J McEntire; David N Herndon; Ronald P Mlcak; Oscar E Suman
Journal:  Microcirculation       Date:  2017-05       Impact factor: 2.628

5.  Contemporary Burn Survival.

Authors:  Karel D Capek; Linda E Sousse; Gabriel Hundeshagen; Charles D Voigt; Oscar E Suman; Celeste C Finnerty; Kristofer Jennings; David N Herndon
Journal:  J Am Coll Surg       Date:  2018-03-09       Impact factor: 6.113

Review 6.  Metabolic implications of severe burn injuries and their management: a systematic review of the literature.

Authors:  Bishara S Atiyeh; S William A Gunn; Saad A Dibo
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

Review 7.  The hepatic response to thermal injury: is the liver important for postburn outcomes?

Authors:  Marc G Jeschke
Journal:  Mol Med       Date:  2009-04-10       Impact factor: 6.354

Review 8.  Is propranolol of benefit in pediatric burn patients?

Authors:  Celeste C Finnerty; David N Herndon
Journal:  Adv Surg       Date:  2013

9.  The effects of selective beta-adrenergic blockade on bone marrow dysfunction following severe trauma and chronic stress.

Authors:  Elizabeth S Miller; Camille G Apple; Kolenkode B Kannan; Zackary M Funk; Philip A Efron; Alicia M Mohr
Journal:  Am J Surg       Date:  2020-07-25       Impact factor: 2.565

10.  Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.

Authors:  Danielle C Orrey; Omar I Halawa; Andrey V Bortsov; Jeffrey W Shupp; Samuel W Jones; Linwood R Haith; Janelle M Hoskins; Marion H Jordan; Shrikant I Bangdiwala; Brandon R Roane; Timothy F Platts-Mills; James H Holmes; James Hwang; Bruce A Cairns; Samuel A McLean
Journal:  Clin J Pain       Date:  2015-01       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.